A Case of Neuromyelitis Optica Spectrum Disorder With Improvement in Urinary Retention After the Administration of Ravulizumab.

Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disease that causes recurrent neuritis and myelitis. Ravulizumab, a complement protein C5 inhibitor, was developed to treat NMOSD. However, its efficacy in improving symptoms remains unclear. This case report describes the case of a 30-year-old woman with NMOSD who developed thoracic myelitis. Initial treatment with high-dose methylprednisolone and hemodialysis alleviated paraplegia, although urinary retention persisted. Two months after initiating ravulizumab treatment, urinary function improved. Ravulizumab administration may have contributed to the improved urinary retention.